Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2023

Code : CMI3809

Pages :165

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Liver Diseases Therapeutics Market: Key Developments

On August 5, 2022, Metadeq Diagnostics, U.K. based diagnostic startup, announced that it has developed a noninvasive blood test that can bypass the need for liver biopsies when diagnosing the severity of liver disease. The test was developed with collaborators from King's College, U.K. based research university, and it is intended to measure and stage nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and liver fibrosis, which can eventually progress to cirrhosis of the liver.

On September 22, 2021, Mirum Pharmaceuticals Inc., U.S. based pharmaceutical company, entered into an agreement with Takeda Pharmaceuticals Co. Ltd, a Japan-based healthcare company for the development and commercialization of maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Maralixibat is an investigational, orally administered medication. It is being evaluated globally for ALGS, PFIC, and BA.

On February 23, 2023, Predictive Health Intelligence Ltd., U.K. based medical technology company, launched hepatoSIGHT, a data-driven tool for the identification of undiagnostic liver disease using historic blood tests.

On September 19, 2022, Genfit, France based biotechnology company, announced that it had entered into an agreement to acquire Versantis AG, Switzerland-based pharmaceutical company, to expand its liver disease portfolio. The acquisition by Genfit is to become a global leader in acute on chronic liver failure. Genfit will also further expand its pipeline in other liver diseases characterized by high unmet medical needs with additional product candidates developed by Versantis.